The FINANCIAL -- Osaka, Japan, September 8, 2011 – Takeda Pharmaceutical Company Limited announced that SYR-472 has entered into phase III clinical trials in Japan to evaluate its safety and efficacy for the treatment of type 2 diabetes.

Discovered by Takeda San Diego, Inc., a Takeda wholly-owned subsidiary located in San Diego, California, SYR-472 is a dipeptidyl peptidase-IV (DPP-4) inhibitor, which blocks DPP-4. DPP-4 is an enzyme that selectively degrades two of the hormones that increase insulin secretion, thereby increasing insulin secretion and lowering blood glucose levels. SYR-472 is a once-weekly oral formulation, expected to help control blood glucose level as well as to improve medication compliance in patients who receive treatment for type 2 diabetes.

Takeda is vigorously continuing its development activities to offer a new treatment option to type 2 diabetes patients with a range of clinical conditions.

Related Stories

• New Phase 3 data for Tradjenta tablets in black or African American patients with type 2 diabetes
• Innovative public-private collaboration launches to tackle antibiotic research
• Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure